Since October 2022, there have been frequent changes in the executives of pharmaceutical companies, including multinational pharmaceutical companies such as Merck, Novartis, and GSK, as well as local pharmaceutical companies
such as Yingen Biologics and Sihe Genetics.
For example, Tian Yu will officially return to his old club Novartis from Merck on November 10 as the head of immunotherapy field of innovative drugs in China, based in Shanghai, and directly reporting to Zhang Ying
, president of Novartis Innovative Drugs China.
On October 31, Yan Qiong, head of immunotherapy at Novartis' original Innovative Drugs China, resigned and will join Menarini as CEO of Menarini China on November 1, reporting directly to Maurizio Luongo, CEO of Menarini Asia-Pacific, based in Shanghai
.
On October 27, Merck announced management changes and appointed CEO Robert Davis as chairman, replacing Kenneth Fraser, who stepped down as CEO last year, effective
December 1.
News on October 25, foreign media reported that Roger Connor, head of GSK vaccines, will leave to seek a new position
outside the company.
At the same time, GSK has also made changes
to some executives.
For example, Chief Commercial Officer Luke Miels, in collaboration with R&D and Supply, will have overall responsibility for strategic commercial product development for vaccines, while continuing to be responsible for strategic product development and commercialization of product portfolios for specialty and general drugs; RIgis Simard, President of Global Supply Chain, is responsible for the supply of vaccines and pharmaceuticals; Deborah Waterhouse, CEO of ViiV Healthcare, will have overall responsibility for GSK Global Health
.
From October 24, Brecht Vanneste, the current Managing Director of Merck Belgium and Luxembourg, officially took over the position of head of Merck China Oncology Business Unit, reporting
directly to Anna Tian, President of Merck China.
In addition, former Novartis executive Jerh Collins will officially take over as Juan Andres on January 1, 2023, having previously served as head of
Novartis' global chemicals operations and anti-infective drugs.
Behind the frequent changes in the executives of multinational pharmaceutical companies, the changes in the pharmaceutical industry are accelerating, and the performance of multinational pharmaceutical companies is under pressure and changing
.
In addition to executive changes, many multinational pharmaceutical companies have reduced their staff, such as Cyclerion Therapeutics and oncoSec Medical
, two new biotechnology companies that lost their staff in October.
According to Cyclerion Therapeutics, the attrition was due to changes
in clinical development plans.
However, some analysts believe that the "money shortage" is the root cause of its forced adjustment of plans and staff reduction, and oncoSec Medical is also facing the same problem
.
It is worth mentioning that the competition for talents between multinational pharmaceutical companies and local pharmaceutical companies has also become more intense, and in recent years, it can be seen that many executives who have left multinational pharmaceutical companies have chosen domestic pharmaceutical companies as their new owners
.
For example, on October 19, Dr.
Huang Yue, former head of translational medicine at Merck China, joined Sihe Gene as Chief Translational Science Officer (CTO), responsible for the preclinical and clinical research and development of
Sihe Gene's independent innovation antisense oligonucleic acid drug research and development project.
Huang Yue's background introduction shows that he has worked in multinational pharmaceutical companies such as Genentech, Novartis, Merck Serono, and worked at Simcere Pharmaceutical for two years, during which he served as the executive director of Simcere Pharmaceutical and the person in charge of the planning and construction of Beijing Translational Science Platform, managing the clinical phase III implementation and progress
of the innovative drug pipeline.
On October 3, Yingen Biologics appointed Antoine Yver as the chairman of the company's scientific advisory board, which will provide scientific advice and guidance for the company's R&D and pipeline development, further enhance the company's innovation position in the ADC field, and contribute to the company's global development strategy
.
Dr.
Antoine Yver is currently the Chairman of Global Development Strategy of Centessa Pharmaceuticals and an independent director of
Sanofi.
Previously, he served as Executive Vice President, President and Global Head of Oncology R&D, and Chairman of
the Cancer Business Unit.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
